文献速递自身炎症与 IgG4 相关病

外周血UBA1变异负荷预测VEXAS综合征不良结局:全国性前瞻性研究

Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.
PubMed 文献 · Ann Rheum Dis · 2026-04-01

该日本全国性前瞻性注册研究纳入60例携带致病性UBA1变异的VEXAS综合征患者(均为男性,中位年龄74岁),并设45例无UBA1变异的VS样综合征男性对照,随访1年。多变量Cox回归显示,较高基线VAF和较高泼尼松龙剂量独立预测不良预后(死亡或输血依赖),且携带UBA1 p.Met41Leu变异者生存更好。

要点

  • 基线UBA1 VAF较高与死亡或输血依赖风险独立相关。
  • 较高泼尼松龙剂量亦独立预测不良预后。
  • UBA1 p.Met41Leu变异者调整发病后生存更好。

核心结论

  • 基线致病性UBA1 VAF是VEXAS综合征不良结局的有效预后生物标志物,有助于风险分层。

研究设计与样本

  • 日本全国性前瞻性注册研究,对疑似病例行下一代测序检测UBA1变异并估算基线VAF。
  • 纳入60例携带致病性UBA1变异的VEXAS综合征患者(均为男性,中位年龄74岁),45例无UBA1变异的VS样综合征男性为对照。
  • 每3个月评估疾病活动度(VEXASCAF)、血清CRP、泼尼松龙剂量、不良事件、死亡和输血依赖,随访1年。

主要发现

  • 中位随访343天期间,VEXASCAF和CRP水平下降,泼尼松龙剂量无显著变化。
  • 1年内50%患者发生≥3级不良事件。
  • 多变量Cox回归中,较高基线VAF和较高泼尼松龙剂量独立预测不良预后(死亡或输血依赖)。
  • 较高VAF与不良结局的关联在34例独立VEXAS患者中得到验证。
  • 调整发病后,携带UBA1 p.Met41Leu变异者生存更好;VS样综合征患者预后同样较差。

关键数值与推荐

  • 不良预后定义为死亡或输血依赖。
  • 中位随访343天,1年内≥3级不良事件发生率为50%。

临床怎么用

  • 对VEXAS综合征患者可检测基线UBA1 VAF以辅助风险分层。
  • 较高基线VAF和较高泼尼松龙剂量提示不良预后风险增高,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Vacuole, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome (VS) is a severe autoinflammatory disease caused by acquired pathogenic UBA1 variants and is associated with high mortality. This study aimed to identify predictors of poor outcomes in VEXAS syndrome. METHODS: We conducted a nationwide prospective registry in Japan, in which all suspected cases underwent next-generation sequencing to detect pathogenic UBA1 variants and estimate the variant allele frequency (VAF) at baseline. Disease activity (VEXAS Current Activity Form [VEXASCAF]), serum C-reactive protein (CRP) level, prednisolone (PSL) dose, adverse events (AEs), mortality, and transfusion dependency were evaluated every 3 months for 1 year. RESULTS: Among the screened patients, we included 60 patients with pathogenic UBA1 variants (all males; median age, 74 years) and 45 male patients with VS-like syndrome of similar age but without UBA1 variants served as controls. During a median follow-up of 343 days, the VEXASCAF and CRP levels decreased, whereas the PSL dose did not significantly change. Grade ≥3 AEs occurred in 50% of patients within 1 year. In the multivariable Cox regression analysis, a higher baseline VAF and higher PSL dose independently predicted poor prognosis, defined as death or transfusion dependence. The association between a higher VAF and poor outcomes was confirmed in 34 independent patients with VS. After adjusting for disease onset, patients carrying the UBA1 p.Met41Leu variant showed better survival. A similarly poor prognosis was observed in VEXAS-like patients. CONCLUSIONS: Baseline pathogenic UBA1 VAF serves as a potent prognostic biomarker for poor outcomes in VS and highlights its potential role in risk stratification.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kirino Y, Maeda A, Higashitani K, et al. Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study. Ann Rheum Dis. 2026. PMID: 41927375. doi:10.1016/j.ard.2026.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。